These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjögren's syndrome. Sato EH; Sullivan DA Invest Ophthalmol Vis Sci; 1994 Apr; 35(5):2632-42. PubMed ID: 8163351 [TBL] [Abstract][Full Text] [Related]
67. [The immunosuppressive agents. 3. The immunosuppressive agents in hematology]. Meshaka G; Jacquillat C; Sultan Y Presse Med (1893); 1967 Jul; 75(32):1653-5. PubMed ID: 6067478 [No Abstract] [Full Text] [Related]
68. Pentostatin (Nipent) and high-dose cyclophosphamide for the treatment of refractory autoimmune disorders. Goodman M Semin Oncol; 2000 Apr; 27(2 Suppl 5):67-71. PubMed ID: 10877056 [TBL] [Abstract][Full Text] [Related]
69. [Pemphigus vulgaris. Clinical aspects, pathophysiology and therapy of a bullous autoimmune dermatosis]. Sunderkötter CH; Luger TA Med Monatsschr Pharm; 1995 Sep; 18(9):255-63. PubMed ID: 7476660 [No Abstract] [Full Text] [Related]
70. Practical Management of Immunosuppressants in Dermatology. Leis-Dosil VM; Prats-Caelles I Actas Dermosifiliogr (Engl Ed); 2018; 109(1):24-34. PubMed ID: 28964393 [TBL] [Abstract][Full Text] [Related]
71. [Pathogenesis and therapy of autoimmune diseases]. Burgio GR Monatsschr Kinderheilkd (1902); 1972 Mar; 120(3):112-9. PubMed ID: 4401605 [No Abstract] [Full Text] [Related]
72. [Experience with immunosuppressive therapy in internal medicine]. Rhomberg F; Siegenthaler W Schweiz Med Wochenschr; 1967 Feb; 97(8):255-9. PubMed ID: 5598379 [No Abstract] [Full Text] [Related]
73. [Bases of immunosuppression and immunostimulation including their side effects in immunopathological diseases]. Deicher H Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():773-82. PubMed ID: 612054 [No Abstract] [Full Text] [Related]
74. [Current status of immunosuppressive therapy in non-neoplastic disorders]. Grob PJ Schweiz Med Wochenschr; 1970 Apr; 100(16):703-7. PubMed ID: 4946733 [No Abstract] [Full Text] [Related]
75. Editorial: Immunosuppressive therapy in active chronic hepatitis. Br Med J; 1973 Nov; 4(5890):441-2. PubMed ID: 4758443 [No Abstract] [Full Text] [Related]
76. Methotrexate management of immune-mediated cochleovestibular disorders. Sismanis A; Wise CM; Johnson GD Otolaryngol Head Neck Surg; 1997 Feb; 116(2):146-52. PubMed ID: 9051055 [TBL] [Abstract][Full Text] [Related]
77. Ciclosporin (cyclosporin A): prototype of a new generation of immunosuppressive drugs. Bendtzen K Allergy; 1984 Nov; 39(8):565-71. PubMed ID: 6397073 [No Abstract] [Full Text] [Related]
78. Suppressive and substitutive immunotherapy: an essay with a review of recent literature. Nydegger UE Immunol Lett; 1985; 9(4):185-90. PubMed ID: 3888832 [No Abstract] [Full Text] [Related]
79. Treatment of autoimmune uveitis. Whitcup SM; Nussenblatt RB Ann N Y Acad Sci; 1993 Nov; 696():307-18. PubMed ID: 8109836 [TBL] [Abstract][Full Text] [Related]
80. Combination therapy: the risks of infection and tumor induction. Yocum DE Springer Semin Immunopathol; 2001; 23(1-2):63-72. PubMed ID: 11455862 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]